Physician profile
Stephen Carl Mathai
NPI 1235242314
$90,977.06
in general payments reported to CMS, 2019-2025
5 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,860 · 2021: $6,355 · 2022: $5,800 · 2023: $11K · 2024: $38K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Travel and Lodging: $19K · Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,402.50 |
| Travel and Lodging | $19,044.65 |
| Food and Beverage | $1,701.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53,094.50 | 2022-2025 | Winrevair |
| United Therapeutics Corporation | $15,995.25 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $12,943.03 | 2020-2024 | Uptravi, Opsumit |
| Actelion Pharmaceuticals, LTD | $8,826.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $117.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mathai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.